12 February 2025 - People with liver, ovarian, and neuroendocrine cancers will have access to more medicines from 1 March 2025.

PHARMAC will fund:

• Atezolizumab and bevacizumab for liver cancer that can’t be removed by surgery
• Bevacizumab for advanced ovarian cancer
• Lanreotide acetate for neuroendocrine cancers, bowel blockages caused by cancer and acromegaly

Read PHARMAC press release